This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Glaucoma  • Randomized Controlled Trial  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

Albert Alm, MD; John Schoenfelder, PhD; Jacquie McDermott, PhD

Arch Ophthalmol. 2004;122:957-965.

Objective  To evaluate the 5-year safety and efficacy of adjunctive 0.005% latanoprost once daily.

Methods  Patients with primary open-angle or exfoliation glaucoma who completed a 3-year, open-label, uncontrolled, prospective trial could enter a 2-year extension phase. High-resolution color photographs of irides were taken at baseline and at 14 subsequent visits. Photographs were assessed for change in iris pigmentation compared with baseline. Intraocular pressures and adverse events were recorded.

Main Outcome Measure  Development and progression of increased iris pigmentation over 5 years.

Results  Of the 519 original patients, 380 enrolled in the extension phase with approximately 89% having an eye color known to be susceptible to color change. After 5 years, most patients had no increase in iris pigmentation, but certain colored irides exhibited notably greater susceptibility than others. For those whose irides did change, onset occurred during the first 8 months in 74% and during the first 24 months in 94%. No patient developed an increase in pigmentation after month 36; the rate of progression decreased over time. Adverse event profiles were similar for patients with and without increased pigmentation. The overall mean intraocular pressure reduction from baseline of 25% was sustained with no need for change in intraocular pressure–lowering treatment in 70% of the eyes.

Conclusion  Latanoprost therapy is safe and well tolerated for long-term treatment of open-angle glaucoma.

From Department of Neuroscience, Ophthalmology, University Hospital, Uppsala, Sweden (Dr Alm); and Pharmacia Ltd, London, England (Drs Schoenfelder and McDermott). The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Reporting the Results of Randomized Clinical Trials: A Priority of Archives of Ophthalmology
Roy W. Beck
Arch Ophthalmol. 2004;122(7):1038-1039.
EXTRACT | FULL TEXT  

Fish Stories and Clinical Trials
William C. Frayer and William J. Frayer
Arch Ophthalmol. 2004;122(7):1049-1051.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Heterochromia
Rehman
CMAJ 2008;179:447-448.
ABSTRACT | FULL TEXT  

A Study of Histopathological Features of Latanoprost-Treated Irides With or Without Darkening Compared With Non-Latanoprost-Treated Irides
Albert et al.
Arch Ophthalmol 2008;126:626-631.
ABSTRACT | FULL TEXT